Company: TXG
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001770787-25-000018
Chunk: 76

Company: 10x Genomics, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 76
---
 that Vested During Year for Non-PEO NEOs 
 ($)                                                                                                                                         |     |            | Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs 
 ($)                                                                                                  |     |   | Average Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Non-PEO NEOs 
 ($)                                                                                                        |     |            | Total - Average Inclusion of   
 Equity Values for Non-PEO NEOs 
 ($)                            |
| 2024 |     | 1,331,283 |                                                                                                                                 |     | -3,847,527 |                                                                                                                         |     | 223,140 |                                                                                                               |     | -1,186,393 |                                                                                                                                             |     | -1,660,885 |                                                                                                      |     | — |                                                                                                            |     | -5,140,382 |                                |

(4) The Peer Group TSR set forth in this table utilizes the Nasdaq Biotechnology Composite Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report for the year ended December 31, 2024. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Nasdaq Biotechnology Composite Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.

(5) We determined stock priceto be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and Non-PEO NEOs in 2024. The amounts in the column represent the closing price on the last trading day of the listed year.

#### 10X GENOMICS, INC.662025 PROXY STATEMENT
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid, Company Total Shareholder Return (“TSR”) and Cumulative TSR Comparison

The following chart sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our Non-PEO NEOs and the Company’s cumulative TSR over the five most recently completed fiscal years. The chart also compares the Company’s TSR to that of the Nasdaq Biotechnology Composite Index over the same period.

#### 10X GENOMICS, INC.672025 PROXY STATEMENT
Relationship Between PEO and Non-PEO NEO Compensation Actually Paid and Net Income

The following chart sets forth the